Company news

Fortress Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

December 14, 2020

Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

November 8, 2020

Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

November 3, 2020

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

September 13, 2020

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

August 27, 2020

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

August 25, 2020

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

August 11, 2020

Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

August 9, 2020

Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

July 30, 2020

Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

July 28, 2020

Fortress Biotech Added to Russell 3000® Index

June 28, 2020

Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

June 10, 2020

Fortress Biotech to Host Virtual Annual Meeting of Stockholders

June 1, 2020

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

May 10, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

May 7, 2020

Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program

March 22, 2020

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

March 15, 2020

Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

February 23, 2020

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

February 12, 2020

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

January 15, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

December 22, 2019

Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

November 11, 2019

← Newer news releases

Calls

Decks

The 5 newest of 24 decks. Every deck is listed under its year.